News Headlines

  1. Signing Of An Agreement To Establish A Joint Venture For The Manufacture Of Biosimilars 11/25/2025

    Alfresa Holdings Corporation (head office: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter “Alfresa Holdings”); Kidswell Bio Corporation (head office: Chuo-ku, Tokyo; President & CEO: Shinya Kurebayashi; hereinafter “Kidswell”); Chiome Bioscience Inc. (head office: Shibuya-ku, Tokyo; President & CEO: Masamichi Koike; hereinafter “Chiome”), and Mycenax Biotech Inc. (head office: Hsinchu, Taiwan; CEO and President : Pei-Jiun Chen; hereinafter “Mycenax”) have now concluded an agreement to establish a joint venture for the manufacture of active pharmaceutical ingredients (APIs) and drug products for biosimilars (hereinafter “Biosimilars”)*1, following the basic agreement*2 the four companies reached on October 6 2025.

  2. Caring Cross And Amrita Research Center Delhi, Amrita Vishwa Vidyapeetham Announce Strategic Partnership To Advance Affordable Cell and Gene Therapies For Underserved Populations Across India 11/25/2025

    Caring Cross, a U.S.-based non-profit dedicated to expanding global access to advanced therapies, today announced a new partnership with the Amrita Research Center Delhi (ARCD) and Amrita Vishwa Vidyapeetham, a leading multi-campus, research-intensive university in India.

  3. medac CDMO Supports Urogen Pharma's Advancement Of UGN-103 11/24/2025

    This collaboration reflects a commitment to advancing meaningful therapies and ensuring patients worldwide gain access to effective, reliable treatment options.

  4. ToolGen And GenEditBio Enter Strategic Cross-License Agreement To Accelerate Development Of Innovative Genome-Editing Therapeutics 11/24/2025

    ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems.

  5. Made Scientific And Cellergy Therapeutics Announce Manufacturing Partnership To Advance First-In-Human Mitochondrial Therapy 11/24/2025

    Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), and Cellergy Therapeutics Ltd., a biotechnology company pioneering first-in-class mitochondrial transplantation therapies, today announced a manufacturing partnership to advance Cellergy's mitochondrial therapy CLG-001 toward first-in-human clinical studies.

  6. Microsize And Schedio Group To Acquire Lonza's Micro-Macinazione Site In Switzerland 11/24/2025

    Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-Macinazione (Mic Mac), a dedicated micronization facility in Monteggio, Switzerland, from Lonza.

  7. Biodlink And Lepu Biopharma Celebrate Successful Launch Of The World's First EGFR-Targeting ADC Drug, Marking A Major Milestone In Mutual Collaboration In Biologics CMC 11/21/2025

    On November 20, 2025, BioDlink (Stock Code: 1875.HK), a leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market launch of MEIYOUHENG®(Becotatug Vedotin injection) , the world's first EGFR-targeting antibody-drug conjugate (ADC).

  8. HRV Pharma And MetroChem Forge Strategic CDMO Alliance To Fast-Track High-Value NCE-1 API Development 11/21/2025

    HRV Global Life Sciences (HRV Pharma), India's first integrated Virtual API and Pharmtech company, today announced a unique, comprehensive, multi-year Contract Development & Manufacturing (CDMO) partnership with MetroChem API Pvt. Ltd., one of India's leading API development and manufacturing companies.

  9. AGC Biologics To Manufacture AAVantgarde's Dual-Vector Gene Therapies For Inherited Retinal Disorders 11/21/2025

    On the heels of AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics’ latest advancement in the adeno-associated virus market.

  10. AstraZeneca Plans $2B Manufacturing Investment In Maryland, Supporting 2,600 Jobs And Catalysing Economic Growth 11/21/2025

    AstraZeneca today announces plans to invest $2B to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials.